• PPP1R3G–PP1γ Activates RIPK1 in Cell Death

  2026-09-24

  A sensitized genome-wide CRISPR screen identified PPP1R3G as a regulator that brings PP1γ to RIPK1, removing inhibitory phosphorylation and enabling RIPK1-dependent apoptosis and type I necroptosis. The findings connect a specific phosphatase-recruitment mechanism to cell-death outcomes in cultured cells and TNF-induced systemic inflammation in mice.

• Grazoprevir/Elbasvir: Evidence and Clinical Context

  2026-09-24

  Vallet-Pichard and Pol review the rationale and clinical evidence for combining grazoprevir, an HCV NS3/4A protease inhibitor, with the NS5A inhibitor elbasvir. The review places this interferon-free regimen within a broader shift toward short, well-tolerated direct-acting antiviral combinations, while emphasizing that genotype, resistance, liver disease, and treatment history shape how outcomes should be interpreted.

• A40926 Workflows for Antibiotic Research

  2026-09-23

  A40926 supports two complementary research paths: testing cell-wall inhibition in susceptible bacteria and improving glycopeptide production through strain and medium engineering. This guide turns reported assay and fermentation data into practical workflows, with checkpoints for interpreting MICs and troubleshooting variable yields.

• Vorinostat and the RNA Pol II Death Signal

  2026-09-23

  Vorinostat is more than a conventional HDAC inhibitor: it is a tractable probe for connecting chromatin remodeling to mitochondrial apoptosis. Building on Harper et al.’s discovery of the Pol II degradation-dependent apoptotic response, this article outlines how translational researchers can test whether Vorinostat-driven cell death reflects transcriptional stress, loss of RNA Pol IIA, or both.

• Bifendate (DDB): Applied Liver Research Workflows

  2026-09-22

  Bifendate (DDB) combines hepatoprotection, lipid-metabolism regulation, and multi-step autophagy inhibition in a practical research tool. This guide translates those properties into reproducible cell, animal, and pharmacokinetic workflows while emphasizing formulation, assay interpretation, and CYP3A4-related safety limits.

• Microfluidized Dextran Microgels in Colon Cancer

  2026-09-22

  The reference study develops an orally administered, sequentially targeted microgel system that releases cisplatin/SPION lipid nanoparticles in the colon. Its combination of dextranase-triggered release, folate-receptor targeting, chemotherapy, and magnetothermal treatment improved local tumor control in orthotopic colon cancer models while limiting systemic exposure.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-09-21

  The reference study shows that naturally occurring angiotensin peptides can enhance SARS-CoV-2 spike binding to host receptors, with the strongest effects associated with selected N-terminally truncated peptides such as angiotensin IV. Its comparative peptide design connects renin–angiotensin biology with viral-entry research while also defining important limits: the evidence comes from antibody-based binding assays rather than infection or clinical studies.

• Pravastatin Sodium: An Assay Interpretation Guide

  2026-09-21

  Pravastatin sodium research is strongest when target inhibition, cellular cholesterol handling, viability, and transporter context are interpreted together. This guide develops a decision-focused assay framework informed by recent human hepatocyte evidence and practical product data.

• Hydrocortisone B1951: Practical Research Workflow

  2026-09-20

  Hydrocortisone B1951 provides a controlled glucocorticoid stimulus for receptor, inflammation, endothelial barrier, and stress-response experiments. It is suitable for workflows that can accommodate a DMSO stock, but it should not be added directly to aqueous media or treated as a universal dose standard for cell or animal studies.

• Annexin V-Cy5/DAPI Apoptosis Kit Workflow

  2026-09-19

  Build a rapid, two-parameter cell apoptosis assay that separates phosphatidylserine exposure from loss of membrane integrity. This workflow applies the kit to TKI-response studies, mitochondrial apoptosis research, microscopy, and flow cytometry while highlighting controls and troubleshooting decisions.

• Milk-Derived EV Uptake in Intestinal Stem Cell Models

  2026-09-18

  This study establishes porcine intestinal stem cell–based models to examine milk-derived extracellular vesicle uptake across intestinal regions and epithelial polarities. Its main contribution is showing that uptake is apically oriented, regionally variable, and sensitive to endocytosis inhibition, providing a more physiological framework than conventional intestinal cell lines.

• Tetracycline Hydrochloride: Assay Design Guide

  2026-09-18

  Tetracycline Hydrochloride is a bacteriostatic antibiotic whose ribosomal mechanism makes it a valuable orthogonal control in antimicrobial and skin microbiome assays. This guide shows how to separate bacterial translation inhibition from rapid ROS-driven cancer-cell death when designing mechanistically interpretable experiments.

• Angiotensin III: A Translational RAAS Strategy

  2026-09-17

  Angiotensin III is more than a downstream RAAS fragment: it is a mechanistic probe for receptor bias, aldosterone biology, pressor signaling, and emerging peptide–viral receptor interactions. This article outlines how to position Angiotensin III (human, mouse) in rigorous translational workflows while separating established physiology from early cross-domain hypotheses.

• Dynamic LRIG1 in Salivary Gland Development

  2026-09-17

  This study integrates single-cell RNA sequencing with qRT-PCR, immunofluorescence, RNAscope, and functional assays to map dynamic LRIG1 expression during murine submandibular gland development. Its findings place LRIG1 in developing epithelial and mesenchymal compartments, with notable association with acinar and basal progenitor populations, while also identifying testable regulatory and functional directions.

• Torin2: Measure mTOR Response, Not Just Viability

  2026-09-16

  Torin2 is a potent mTOR inhibitor for dissecting pathway activity, growth arrest, and cell death in cancer research. This guide combines its pharmacology with a response-measurement framework that helps researchers distinguish reduced viability from true cytotoxicity.

3620 records 1/242 page Next 12345 下5页 Last page